← Back to Search

Dietary Supplement

Naltrexone for Coronavirus

Phase 2
Waitlist Available
Led By Sajad Zalzala, MD
Research Sponsored by AgelessRx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This trial is testing if low doses of the drugs naltrexone and NAD+ can help treat patients with post-COVID-19 syndrome.

Eligible Conditions
  • Coronavirus
  • Long COVID Syndrome
  • Post-COVID Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Reduction of fatigue in post-COVID-19 syndrome by treatment with LDN and NAD+
Secondary outcome measures
Improvement of quality of life in post-COVID-19 syndrome by treatment with LDN and NAD+.

Side effects data

From 2011 Phase 4 trial • 165 Patients • NCT00006489
24%
Nausea
12%
Headache
12%
Cold
10%
Dry Mouth
10%
Fatigue
7%
Gastrointestinal Issues
7%
Muscle Aches
7%
Vomiting
7%
Serious Suicidal Ideation
5%
Constipation
5%
Diarrhea
5%
Stomach Virus
5%
Changes to Vision
5%
Loose Stool
5%
Increased Irritability
5%
Sedation
5%
Stomach Pain
5%
Increased Bowel Movements
2%
Toothache
100%
80%
60%
40%
20%
0%
Study treatment Arm
Naltrexone + Supportive Counseling
Naltrexone + CBT (Prolonged Exposure Therapy)
Placebo + CBT (Prolonged Exposure Therapy)
Placebo + Supportive Counseling

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment with LDN and NAD+Experimental Treatment2 Interventions
LDN will be used at a dosage of 4.5 mg/day, which will be taken orally in the form of tablets. NAD+ will be administered using the IontoPatch iontophoresis patch containing 400 mg of NAD+ solution which is worn on the skin for 4-6 hours once per week.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NAD+
2021
Completed Phase 2
~40
Naltrexone
FDA approved

Find a Location

Who is running the clinical trial?

AgelessRxLead Sponsor
5 Previous Clinical Trials
2,664 Total Patients Enrolled
Sajad Zalzala, MDPrincipal InvestigatorAgelessRx
4 Previous Clinical Trials
2,649 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Kentucky
Virginia
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
2021. "Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04604704.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top